BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Suven Life Sciences Ltd Presenting At International Conference on Alzheimer's Disease (ICAD)


7/12/2010 1:54:19 PM

HYDERABAD, INDIA (Jul 12, 2010) – Several exciting new results and data presentations from Suven’s portfolio of investigational neuroscience new chemical entities (NCEs) are being presented at International Conference on Alzheimer’s Disease (ICAD) at Honolulu, USA during the week of July 12-15, 2010. ICAD is the annual International conference of the Alzheimer’s association and more than 10 thousand Neuro Scientists, clinicians, corporate senior management from all over the world covering all the major Pharma, Biotech and Academic research Institutions would attend this meeting.

Suven’s portfolio has an excellent new molecule which not only treats the cognitive impairment in Alzheimer’s disease symptomatically but also possibly useful in reducing the disease progression. Suven scientists are presenting exciting data on this molecule and other NCE’s on cognitive impairment and memory related disorders, depression and pain.

Alzheimer’s disease has a significant unmet medical need for which current treatment options are insufficient. Suven has a number of in-house drug discovery programs in the area of cognition, focusing on novel approaches that may lead to the development of new therapies for patients in addition to the current clinical candidate SUVN-502.

Suven Life Sciences is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets. The Company has twelve (12) internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, Dementia, Depression, Huntington's disease, Parkinson's disease and obesity in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.

Suven is committed to neuroscience research and is “In search of new CNS therapies for better living.”

For more information on Suven please visit our Web site at http://www.suven.com

Risk Statement: Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES